Locations:
Search IconSearch

Mapping the Learning Curve for Fluoroless Catheter Ablations

Study assesses proficiency gains when treating AF, SVT and PVCs without radiation

20-HVI-1915482-mapping-for-catheter-ablation-650×450

The learning curve to gain proficiency in performing zero-fluoroscopy catheter ablations varies according to the type of ablation, concludes a recent study from Cleveland Clinic researchers published in the Journal of Interventional Cardiac Electrophysiology. The safety and efficacy of low- to no-fluoroscopy ablation has been established, but despite safety benefits from decreased radiation exposure, the practice has not been widely adopted.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

“The biggest obstacle to widespread adoption of fluoroless ablation is operator experience and comfort,” says the study’s principal investigator, Roy Chung, MD, a Cleveland Clinic electrophysiologist. “It can be daunting to change the way you learned to do something, especially in procedures that involve complex anatomy.”

He and colleagues sought to quantify the operator learning curve necessary to perform fluoroless supraventricular (SVT), atrial fibrillation (AF) and premature ventricular contraction (PVC) ablations. They conducted a retrospective, single-center study of a single, junior faculty-level operator (Dr. Chung) pursuing zero fluoroscopy use.

“We thought that if we could identify the volume of cases necessary to achieve proficiency, we could help increase adoption of a practice that allows use of the least amount of radiation as reasonably achievable according to society guidelines,” says Dr. Chung. “We also were interested in pursuing this strategy to mitigate long-term lead wear, which has resulted in orthopaedic injuries. Individuals who benefit the most are our electrophysiology laboratory team members and anesthesia colleagues.”

PVI, SVT and PVC learning curves

The study included 167 patients who underwent ablation from 2016 to 2019. Seventy-seven patients (46%) underwent pulmonary vein isolation for AF, 64 patients (38%) had SVT ablations and 26 (16%) had PVC ablations. 3D electroanatomic mapping was used in all cases. The operator performed SVT ablations using standard atrial and ventricular stimulation. For patients with ventricular arrhythmias, only those with greater than 10% PVC burden received an ablation. All AF ablations were performed under general anesthesia.

Advertisement

“It quickly became clear that fluoroless transseptal access would be our rate-limiting factor,” says Dr. Chung. “An operator can certainly build confidence with this portion of the procedure, but it takes a bit more time.”

Key findings were as follows (see figure below):

  • For SVT ablations, mean fluoroscopy time was reduced from 4.1 ± 3.5 min in the first 10-case increment to 0.8 ± 1.2 min after the 50th case (P = 0.0001), with a 97% success rate.
  • In PVC ablations, the first five cases required a mean fluoroscopy time of 7.7 ± 5.5 min, which dropped to 2.3 ± 3.4 min after the 15th case and then down to 0 min after 20 cases (P = 0.0008). Over 9 ± 9 months of follow-up, 8% of patients (2/26) had recurrence.
  • In the AF ablation group, mean fluoroscopy time dropped from 9.9 ± 3.3 min in the first 20 cases to 2.6 ± 2.3 min after 40 cases, down to 0.1 min after 50 cases (P < 0.0001). Procedure time was reduced from 235 ± 41 min to 170 ± 34 min after 60 cases (P < 0.001), and 8% of patients experienced AF recurrence within 12 months.
  • The steepest learning curve occurred over the first 20, 15 and 40 cases for SVT, PVC and AF ablation, respectively.
Fluoroscopy and procedural time stratified by consecutive cases of AF, SVT and PVC ablation.

Figure. Fluoroscopy and procedural time stratified by consecutive cases of AF, SVT and PVC ablation. Reprinted by permission from Springer Nature, Journal of Interventional Cardiac Electrophysiology, “Operator learning curve and clinical outcomes of zero fluoroscopy catheter ablation of atrial fibrillation, supraventricular tachycardia, and ventricular arrhythmias,” Kochar A, et al. © 2020. Advance online publication 12 June 2020 (doi:10.1007/s10840-020-00798-8).

Advertisement

Out of the comfort zone

Previous studies have established the safety and efficacy of fluoroless catheter ablations; while this is a retrospective, single-site study, its findings offer a look at what it takes to learn a new way of performing ablation procedures.

“We’ve demonstrated that there appear to be distinct learning curves for each procedure, the steepest of which was for transseptal access using only intracardiac echocardiography guidance,” says Dr. Chung. “This was entirely out of our comfort zone at first but proved attainable and even seemed second nature by the end.”

He notes that zero fluoroscopy is not achievable in all circumstances, especially those involving patients with cardiac implantable electronic devices. But, he adds, as the use of three-dimensional mapping programs, contact-force-sensing catheters and intracardiac echo has become more widespread, the opportunity for reduced operator and patient radiation exposure is limited only by operator experience. “Now that we have an idea of what these learning curves look like, we can begin a more widespread adoption of these practices,” Dr. Chung says.

Study co-author Oussama Wazni, MD, concurs. “With a mindful approach, ablation with near-zero fluoroscopy is achievable while minimizing risk and optimizing operator experience,” says Dr. Wazni, Cleveland Clinic’s Section Head of Cardiac Electrophysiology and Pacing.

Advertisement

Related Articles

cardiac echo and cardiac CT images side by side

Indexed CTA Measures Sharpen Risk Prediction in Ascending Aortopathy

Large analysis adds to evidence that absolute diameter alone may miss vulnerable patients

operating room during robotic lung transplant surgery

Successful First Case Launches Cleveland Clinic’s Robotic Lung Transplant Program

Procedure places the center among only a handful worldwide to offer the minimally invasive approach

stylized illustration of cholesterol particle floating in bloodstream

Novel siRNA Produces Deep, Durable Reduction in Lp(a)

Phase 1 trial shows up to 97% decrease through 48 weeks with good tolerability

converging lines on a graph pointing downward

Oxidized Phospholipids Track Closely With Lp(a) Reductions in Clinical Trial

Post hoc ALPACA analysis boosts biological rationale for ongoing outcomes trial of lepodisiran

sight picture overlaid on DNA double helix

Positive Effects of CRISPR-Cas9 Gene Editing for Dyslipidemia Endure Through 1 Year

Durability findings propel potential one-time treatment approach to phase 1b testing

Doctor examining patient's heart with a stethoscope

New Guideline Calls on Cardiologists to Think Beyond Silos When Managing CKM Syndrome

Practical takeaways for the reality of overlapping cardiovascular, kidney and metabolic disease

illustration showing device inserted into heart chambers via blood vessels

IMPACT Trial Supports Safety, Feasibility of Preemptive LV Unloading in High-Risk Cardiac Surgery

First prospective study shows early extubation and low vasoactive/inotropic medication use

Dilated aorta

Reassessing Surgical Thresholds in Ascending Aortic Dilation

Height-indexed aortic measurements may better identify risk than diameter alone

Ad